内部人交易

EDGAR

Taysha Gene Therapies, Inc.

董事、高级管理人员和10%以上股东在SEC表格3、4、5中报告的交易,读取自每份申报文件的XML。代码及其措辞均为SEC原文。

表格4须在交易后两个工作日内提交,因此最近的交易可能尚未申报。

范围:日期在2025年11月18日或之后的交易。

公开市场买入(代码P)
0笔交易,—股
公开市场卖出(代码S)
12笔交易,1,368,795股
股数 × 每股价格之和:6,658,093.26

合计为所列已申报交易之和;它们统计的是已报告的内容,并不表示方向。

显示第1–38项,共38项

内部人交易,最新在前,按SEC表格3、4、5所申报
日期报告人代码取得或处置股数每股价格(按申报)价值(推算)交易后持股直接或间接规则10b5-1勾选框脚注来源
2026年7月10日 申报日期:2026年7月10日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)200,0006.24
1,248,000

推算:股数 × 每股价格。精确值 1248000.00。

936,410直接(D) 是
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
打开申报文件 0001665124-26-000013 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Long Alison S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)21,3350—127,178直接(D) 否
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001891712-26-000002 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Long Alison S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Stock Option (right to buy) — 标的 Common Stock (42,671) — 行权价 5.97
取得(A)42,6710—42,671直接(D) 否
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001891712-26-000002 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Sepp-Lorenzino Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)21,3350—127,178直接(D) 否
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001777421-26-000005 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Sepp-Lorenzino Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Stock Option (right to buy) — 标的 Common Stock (42,671) — 行权价 5.97
取得(A)42,6710—42,671直接(D) 否
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001777421-26-000005 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Donenberg Phillip B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)21,3350—241,289直接(D) 否
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001238120-26-000008 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Donenberg Phillip B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Stock Option (right to buy) — 标的 Common Stock (42,671) — 行权价 5.97
取得(A)42,6710—42,671直接(D) 否
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001238120-26-000008 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)21,3350—1,176,559直接(D) 否
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001709418-26-000002 读取自申报文件的XML 对此行提出异议
2026年6月1日 申报日期:2026年6月2日Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Stock Option (right to buy) — 标的 Common Stock (42,671) — 行权价 5.97
取得(A)42,6710—42,671直接(D) 否
F3
  • F3 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
打开申报文件 0001709418-26-000002 读取自申报文件的XML 对此行提出异议
2026年4月10日 申报日期:2026年4月13日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)19,0211.71
32,525.91

推算:股数 × 每股价格。精确值 32525.91。

1,336,410直接(D) 是— 打开申报文件 0001665124-26-000011 读取自申报文件的XML 对此行提出异议
2026年4月10日 申报日期:2026年4月13日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)200,0004.46
892,000

推算:股数 × 每股价格。精确值 892000.00。

1,136,410直接(D) 是
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
打开申报文件 0001665124-26-000011 读取自申报文件的XML 对此行提出异议
2026年4月10日 申报日期:2026年4月13日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (19,021) — 行权价 1.71
处置(D)19,0210—455,920直接(D) 是
F3
  • F3 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-26-000011 读取自申报文件的XML 对此行提出异议
2026年2月4日 申报日期:2026年2月6日Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)1,6554.52
7,480.6

推算:股数 × 每股价格。精确值 7480.60。

1,442,131直接(D) 否
F1
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
打开申报文件 0001793412-26-000012 读取自申报文件的XML 对此行提出异议
2026年1月26日 申报日期:2026年1月27日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)26,9184.61
124,091.98

推算:股数 × 每股价格。精确值 124091.98。

1,317,389直接(D) 否
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
打开申报文件 0001665124-26-000008 读取自申报文件的XML 对此行提出异议
2026年1月26日 申报日期:2026年1月27日Nolan Sean P. Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)41,3124.61
190,448.32

推算:股数 × 每股价格。精确值 190448.32。

2,908,257直接(D) 否
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
打开申报文件 0001569926-26-000008 读取自申报文件的XML 对此行提出异议
2026年1月26日 申报日期:2026年1月27日Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)23,8494.61
109,943.89

推算:股数 × 每股价格。精确值 109943.89。

1,443,786直接(D) 否
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
打开申报文件 0001793412-26-000008 读取自申报文件的XML 对此行提出异议
2026年1月23日 申报日期:2026年1月27日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)89,1324.75
423,377

推算:股数 × 每股价格。精确值 423377.00。

1,344,307直接(D) 否
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
打开申报文件 0001665124-26-000008 读取自申报文件的XML 对此行提出异议
2026年1月23日 申报日期:2026年1月27日Nolan Sean P. Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)136,7894.75
649,747.75

推算:股数 × 每股价格。精确值 649747.75。

2,949,569直接(D) 否
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
打开申报文件 0001569926-26-000008 读取自申报文件的XML 对此行提出异议
2026年1月23日 申报日期:2026年1月27日Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)78,9684.75
375,098

推算:股数 × 每股价格。精确值 375098.00。

1,467,635直接(D) 否
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
打开申报文件 0001793412-26-000008 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nolan Sean P. Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)1,008,0000—3,086,358直接(D) 否
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001569926-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nolan Sean P. Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (648,000) — 行权价 4.86
取得(A)648,0000—648,000直接(D) 否
F3
  • F3 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001569926-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)111,3240.6989
77,804.3436

推算:股数 × 每股价格。精确值 77804.3436。

1,117,763直接(D) 是— 打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)88,6761.71
151,635.96

推算:股数 × 每股价格。精确值 151635.96。

1,206,439直接(D) 是— 打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)200,0004.71
942,000

推算:股数 × 每股价格。精确值 942000.00。

1,006,439直接(D) 是
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)427,0000—1,433,439直接(D) 是
F3
  • F3 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (111,324) — 行权价 0.6989
处置(D)111,3240—111,359直接(D) 是
F4
  • F4 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (88,676) — 行权价 1.71
处置(D)88,6760—474,941直接(D) 是
F5
  • F5 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Nagendran Sukumar Director · Officer: President and Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (274,000) — 行权价 4.86
取得(A)274,0000—274,000直接(D) 是
F6
  • F6 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Alam Kamran Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
取得(A)359,0000—1,546,603直接(D) 否
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001793412-26-000002 读取自申报文件的XML 对此行提出异议
2026年1月12日 申报日期:2026年1月14日Alam Kamran Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (231,000) — 行权价 4.86
取得(A)231,0000—231,000直接(D) 否
F2
  • F2 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001793412-26-000002 读取自申报文件的XML 对此行提出异议
2025年12月1日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)260,0471.71
444,680.37

推算:股数 × 每股价格。精确值 444680.37。

1,266,486直接(D) 否— 打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年12月1日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)260,0474.51
1,172,811.97

推算:股数 × 每股价格。精确值 1172811.97。

1,006,439直接(D) 否
F2
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年12月1日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (260,047) — 行权价 1.71
处置(D)260,0470—563,617直接(D) 否
F4
  • F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年11月28日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)70,1720.6989
49,043.2108

推算:股数 × 每股价格。精确值 49043.2108。

1,076,611直接(D) 否— 打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年11月28日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
取得(A)39,9531.71
68,319.63

推算:股数 × 每股价格。精确值 68319.63。

1,116,564直接(D) 否— 打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年11月28日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
处置(D)110,1254.75
523,093.75

推算:股数 × 每股价格。精确值 523093.75。

1,006,439直接(D) 否
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年11月28日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (70,172) — 行权价 0.6989
处置(D)70,1720—222,683直接(D) 否
F3
  • F3 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议
2025年11月28日 申报日期:2025年12月1日Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

衍生证券: Employee Stock Option (right to buy) — 标的 Common Stock (39,953) — 行权价 1.71
处置(D)39,9530—823,664直接(D) 否
F4
  • F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
打开申报文件 0001665124-25-000003 读取自申报文件的XML 对此行提出异议

机构持有人(表格13F)

库中没有归属于该发行人的表格13F持仓。尚未关联或尚未申报的持有人是缺失,而不是零。

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5%持有人(附表13D和13G)

此处读取SEC结构化格式(2024年末起)提交的附表。更早的附表是自由文本,不予读取。

5%持有人,最新事件在前,按申报
持有人占该类别比例持股数事件日期表格来源
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.932,785,574.0009/30/2026 申报日期:2026年11月16日SCHEDULE 13G/A第6号修订打开申报文件 0001346824-26-000295 对此行提出异议
Peter Kolchinsky Common Stock, $0.00001 par value per share9.932,785,574.0009/30/2026 申报日期:2026年11月16日SCHEDULE 13G/A第6号修订打开申报文件 0001346824-26-000295 对此行提出异议
Rajeev Shah Common Stock, $0.00001 par value per share9.932,785,574.0009/30/2026 申报日期:2026年11月16日SCHEDULE 13G/A第6号修订打开申报文件 0001346824-26-000295 对此行提出异议
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.932,785,574.0009/30/2026 申报日期:2026年11月16日SCHEDULE 13G/A第6号修订打开申报文件 0001346824-26-000295 对此行提出异议
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.932,886,242.0006/30/2026 申报日期:2026年8月14日SCHEDULE 13G/A第5号修订打开申报文件 0001231919-26-000928 对此行提出异议
Peter Kolchinsky Common Stock, $0.00001 par value per share9.932,886,242.0006/30/2026 申报日期:2026年8月14日SCHEDULE 13G/A第5号修订打开申报文件 0001231919-26-000928 对此行提出异议
Rajeev Shah Common Stock, $0.00001 par value per share9.932,886,242.0006/30/2026 申报日期:2026年8月14日SCHEDULE 13G/A第5号修订打开申报文件 0001231919-26-000928 对此行提出异议
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.932,886,242.0006/30/2026 申报日期:2026年8月14日SCHEDULE 13G/A第5号修订打开申报文件 0001231919-26-000928 对此行提出异议
Morgan Stanley Common Stock5.116,244,33906/30/2026 申报日期:2026年8月13日SCHEDULE 13G/A第2号修订打开申报文件 0000895421-26-000269 对此行提出异议
Morgan Stanley Capital Services LLC Common Stock5.016,001,13006/30/2026 申报日期:2026年8月13日SCHEDULE 13G/A第2号修订打开申报文件 0000895421-26-000269 对此行提出异议
Vestal Point Capital, LP Common Stock, par value $0.00001 per share6.318,000,000.0003/31/2026 申报日期:2026年5月15日SCHEDULE 13G/A第1号修订打开申报文件 0000902664-26-002553 对此行提出异议
Ryan Wilder Common Stock, par value $0.00001 per share6.318,000,000.0003/31/2026 申报日期:2026年5月15日SCHEDULE 13G/A第1号修订打开申报文件 0000902664-26-002553 对此行提出异议
RTW Investments, LP Common Stock, par value $0.00001 per share7.020,689,084.0003/31/2026 申报日期:2026年5月15日SCHEDULE 13G/A第5号修订打开申报文件 0001493215-26-000122 对此行提出异议
Roderick Wong Common Stock, par value $0.00001 per share7.020,689,084.0003/31/2026 申报日期:2026年5月15日SCHEDULE 13G/A第5号修订打开申报文件 0001493215-26-000122 对此行提出异议
RTW Investments, LP Common Stock, par value $0.00001 per share8.323,407,133.0012/31/2025 申报日期:2026年2月17日SCHEDULE 13G/A第4号修订打开申报文件 0001493215-26-000050 对此行提出异议
Roderick Wong Common Stock, par value $0.00001 per share8.323,407,133.0012/31/2025 申报日期:2026年2月17日SCHEDULE 13G/A第4号修订打开申报文件 0001493215-26-000050 对此行提出异议
Vestal Point Capital, LP Common Stock, par value $0.00001 per share513,750,000.0012/31/2025 申报日期:2026年2月17日SCHEDULE 13G打开申报文件 0000902664-26-001081 对此行提出异议
Ryan Wilder Common Stock, par value $0.00001 per share513,750,000.0012/31/2025 申报日期:2026年2月17日SCHEDULE 13G打开申报文件 0000902664-26-001081 对此行提出异议
FMR LLC COMMON STOCK4.913,528,365.8712/31/2025 申报日期:2026年2月5日SCHEDULE 13G/A第10号修订打开申报文件 0000315066-26-000536 对此行提出异议
Abigail P. Johnson COMMON STOCK4.913,528,365.8712/31/2025 申报日期:2026年2月5日SCHEDULE 13G/A第10号修订打开申报文件 0000315066-26-000536 对此行提出异议
BlackRock, Inc. Common Stock6.517,852,29112/31/2025 申报日期:2026年1月21日SCHEDULE 13G/A第2号修订打开申报文件 0002012383-26-000794 对此行提出异议
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.927,662,481.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第4号修订打开申报文件 0001231919-25-000491 对此行提出异议
Peter Kolchinsky Common Stock, $0.00001 par value per share9.927,662,481.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第4号修订打开申报文件 0001231919-25-000491 对此行提出异议
Rajeev Shah Common Stock, $0.00001 par value per share9.927,662,481.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第4号修订打开申报文件 0001231919-25-000491 对此行提出异议
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.927,662,481.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第4号修订打开申报文件 0001231919-25-000491 对此行提出异议
Octagon Capital Advisors LP Common Stock, $0.00001 par value3.39,067,500.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第1号修订打开申报文件 0001214659-25-016718 对此行提出异议
Octagon Investments Master Fund Common Stock, $0.00001 par value3.39,067,500.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第1号修订打开申报文件 0001214659-25-016718 对此行提出异议
Ting Jia Common Stock, $0.00001 par value3.39,067,500.0009/30/2025 申报日期:2025年11月14日SCHEDULE 13G/A第1号修订打开申报文件 0001214659-25-016718 对此行提出异议
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.925,345,988.0006/30/2025 申报日期:2025年8月14日SCHEDULE 13G/A第3号修订打开申报文件 0001415889-25-022033 对此行提出异议
Peter Kolchinsky Common Stock, $0.00001 par value per share9.925,345,988.0006/30/2025 申报日期:2025年8月14日SCHEDULE 13G/A第3号修订打开申报文件 0001415889-25-022033 对此行提出异议
Rajeev Shah Common Stock, $0.00001 par value per share9.925,345,988.0006/30/2025 申报日期:2025年8月14日SCHEDULE 13G/A第3号修订打开申报文件 0001415889-25-022033 对此行提出异议
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.925,345,988.0006/30/2025 申报日期:2025年8月14日SCHEDULE 13G/A第3号修订打开申报文件 0001415889-25-022033 对此行提出异议
RTW Investments, LP Common Stock, par value $0.00001 per share9.925,183,287.0006/30/2025 申报日期:2025年8月14日SCHEDULE 13G/A第3号修订打开申报文件 0001415889-25-021712 对此行提出异议
Roderick Wong Common Stock, par value $0.00001 per share9.925,183,287.0006/30/2025 申报日期:2025年8月14日SCHEDULE 13G/A第3号修订打开申报文件 0001415889-25-021712 对此行提出异议
FMR LLC COMMON STOCK6.215,627,821.8706/30/2025 申报日期:2025年8月6日SCHEDULE 13G/A第9号修订打开申报文件 0000315066-25-002098 对此行提出异议
Abigail P. Johnson COMMON STOCK6.215,627,821.8706/30/2025 申报日期:2025年8月6日SCHEDULE 13G/A第9号修订打开申报文件 0000315066-25-002098 对此行提出异议
Morgan Stanley Common Stock6.716,858,64406/30/2025 申报日期:2025年8月6日SCHEDULE 13G/A第1号修订打开申报文件 0000895421-25-000463 对此行提出异议
Morgan Stanley Capital Services LLC Common Stock5.614,095,14306/30/2025 申报日期:2025年8月6日SCHEDULE 13G/A第1号修订打开申报文件 0000895421-25-000463 对此行提出异议
BlackRock, Inc. Common Stock5.213,153,32606/30/2025 申报日期:2025年7月16日SCHEDULE 13G/A第1号修订打开申报文件 0002052113-25-002549 对此行提出异议
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.00001 per share5.112,748,968.0006/26/2025 申报日期:2025年7月3日SCHEDULE 13G打开申报文件 0000769993-25-000401 对此行提出异议
GOLDMAN SACHS CO. LLC Common Stock, par value $0.00001 per share5.112,748,968.0006/26/2025 申报日期:2025年7月3日SCHEDULE 13G打开申报文件 0000769993-25-000401 对此行提出异议

比例是申报文件所指类别的比例,由持有人自行陈述。团体成员各自报告团体的股份,因此各行不应相加。

已读取的内容

已读取2,360,287份申报文件,日期为2004年6月14日至2026年11月17日:表格3, 3/A, 4, 4/A, 5, 5/A。

档案仍在读取时,某些年份可能不完整。某年在此显示的申报较少,并不表示实际提交得少。

按申报年份统计已读取的文件
申报年份已读取文件
201517,836
2016222,374
2017207,870
2018222,268
2019215,153
2020157,831
2021224,474
2022158,941
2023199,811
2024209,823
2025235,520
2026260,174

SEC要求使用XML之前提交的文件只列出,不提取内容。

返回Taysha Gene Therapies, Inc.